Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Similar articles for PubMed (Select 19457353)

1.

Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease.

Drake RR, White KY, Fuller TW, Igwe E, Clements MA, Nyalwidhe JO, Given RW, Lance RS, Semmes OJ.

J Proteomics. 2009 Aug 20;72(6):907-17. doi: 10.1016/j.jprot.2009.01.007. Epub 2009 Jan 20. Review.

2.

Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine.

Principe S, Kim Y, Fontana S, Ignatchenko V, Nyalwidhe JO, Lance RS, Troyer DA, Alessandro R, Semmes OJ, Kislinger T, Drake RR, Medin JA.

J Proteome Res. 2012 Apr 6;11(4):2386-96. doi: 10.1021/pr2011236. Epub 2012 Feb 29.

3.

Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer.

Kim Y, Ignatchenko V, Yao CQ, Kalatskaya I, Nyalwidhe JO, Lance RS, Gramolini AO, Troyer DA, Stein LD, Boutros PC, Medin JA, Semmes OJ, Drake RR, Kislinger T.

Mol Cell Proteomics. 2012 Dec;11(12):1870-84. doi: 10.1074/mcp.M112.017889. Epub 2012 Sep 17.

4.

In-depth proteomic analyses of direct expressed prostatic secretions.

Drake RR, Elschenbroich S, Lopez-Perez O, Kim Y, Ignatchenko V, Ignatchenko A, Nyalwidhe JO, Basu G, Wilkins CE, Gjurich B, Lance RS, Semmes OJ, Medin JA, Kislinger T.

J Proteome Res. 2010 May 7;9(5):2109-16. doi: 10.1021/pr1001498.

5.

Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids.

White KY, Rodemich L, Nyalwidhe JO, Comunale MA, Clements MA, Lance RS, Schellhammer PF, Mehta AS, Semmes OJ, Drake RR.

J Proteome Res. 2009 Feb;8(2):620-30. doi: 10.1021/pr8007545.

6.

Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.

Rehman I, Azzouzi AR, Catto JW, Allen S, Cross SS, Feeley K, Meuth M, Hamdy FC.

Urology. 2004 Dec;64(6):1238-43.

PMID:
15596215
7.

Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.

Fredolini C, Liotta LA, Petricoin EF.

Crit Rev Clin Lab Sci. 2010 May-Jun;47(3):125-38. doi: 10.3109/10408363.2010.503558. Epub 2010 Sep 21. Review.

PMID:
20858067
8.

MALDI MS profiling of post-DRE urine samples highlights the potential of β-microseminoprotein as a marker for prostatic diseases.

Flatley B, Wilmott KG, Malone P, Cramer R.

Prostate. 2014 Jan;74(1):103-11. doi: 10.1002/pros.22736. Epub 2013 Sep 30.

PMID:
24115268
9.

Demonstration of the role of prostate-specific antigen in semen liquefaction by two-dimensional electrophoresis.

Lee C, Keefer M, Zhao ZW, Kroes R, Berg L, Liu XX, Sensibar J.

J Androl. 1989 Nov-Dec;10(6):432-8.

PMID:
2482840
10.

In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.

Principe S, Jones EE, Kim Y, Sinha A, Nyalwidhe JO, Brooks J, Semmes OJ, Troyer DA, Lance RS, Kislinger T, Drake RR.

Proteomics. 2013 May;13(10-11):1667-71. doi: 10.1002/pmic.201200561. Epub 2013 Apr 23.

11.

Relative quantitation of proteins in expressed prostatic secretion with a stable isotope labeled secretome standard.

Zhao T, Zeng X, Bateman NW, Sun M, Teng PN, Bigbee WL, Dhir R, Nelson JB, Conrads TP, Hood BL.

J Proteome Res. 2012 Feb 3;11(2):1089-99. doi: 10.1021/pr200829f. Epub 2011 Dec 1.

PMID:
22077639
12.

Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis.

Gonzalgo ML, Nakayama M, Lee SM, De Marzo AM, Nelson WG.

Urology. 2004 Feb;63(2):414-8.

PMID:
14972513
13.

Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.

Ummanni R, Junker H, Zimmermann U, Venz S, Teller S, Giebel J, Scharf C, Woenckhaus C, Dombrowski F, Walther R.

Cancer Lett. 2008 Aug 8;266(2):171-85. doi: 10.1016/j.canlet.2008.02.047. Epub 2008 Apr 1.

PMID:
18384941
14.

Integrative analysis of N-linked human glycoproteomic data sets reveals PTPRF ectodomain as a novel plasma biomarker candidate for prostate cancer.

Whitmore TE, Peterson A, Holzman T, Eastham A, Amon L, McIntosh M, Ozinsky A, Nelson PS, Martin DB.

J Proteome Res. 2012 May 4;11(5):2653-65. doi: 10.1021/pr201200n. Epub 2012 Apr 19.

PMID:
22494190
15.
16.
17.

Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results.

Crocitto LE, Korns D, Kretzner L, Shevchuk T, Blair SL, Wilson TG, Ramin SA, Kawachi MH, Smith SS.

Urology. 2004 Oct;64(4):821-5.

PMID:
15491741
18.

The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage.

Meid FH, Gygi CM, Leisinger HJ, Bosman FT, Benhattar J.

J Urol. 2001 May;165(5):1802-5.

PMID:
11342979
19.

Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions.

Okamoto A, Yamamoto H, Imai A, Hatakeyama S, Iwabuchi I, Yoneyama T, Hashimoto Y, Koie T, Kamimura N, Mori K, Yamaya K, Ohyama C.

Oncol Rep. 2009 Jan;21(1):73-9.

PMID:
19082445
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk